AbbVie (ABBV)
(Delayed Data from NYSE)
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
How Trading Your Own Retirement Can Fleece Your Financial Future - February 28, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Easy Investing Secrets to an Early Retirement - February 27, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS
by Zacks Equity Research
Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS
One of Your Stock Investments is Being Acquired: Now What?
by Tracey Ryniec
One of your companies gets a buyout offer and the shares soar. There might be different strategies for traders and investors on what to do next.
Signs That Your Trading Will Ruin Your Retirement - February 20, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Easy Investing Secrets to an Early Retirement - February 19, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
ImmunoGen (IMGN) Q4 Earnings & Sales Beat, Shares Rally
by Zacks Equity Research
ImmunoGen (IMGN) reports fourth-quarter results with earnings and revenues beating estimates.
The Keys to Successfully Timing the Markets - February 14, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails
by Kinjel Shah
AbbVie (ABBV) and Allergan (AGN) announce Q4 results.
The Zacks Analyst Blog Highlights: AbbVie, Accenture, TOTAL, Amazon.com and Intuit
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Accenture, TOTAL, Amazon.com and Intuit
How Trading Your Own Retirement Can Fleece Your Financial Future - February 11, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Top Stock Research Reports for AbbVie, Accenture, TOTAL & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Accenture (ACN) and TOTAL (TOT).
Allergan (AGN) Surpasses Q4 Earnings and Sales Estimates
by Kinjel Shah
Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Easy Investing Secrets to an Early Retirement - February 10, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
AbbVie's (ABBV) Q4 Earnings Beat, 2020 View Solid, Stock Up
by Zacks Equity Research
AbbVie (ABBV) beat on earnings in the fourth quarter of 2019 while revenues meet the same. Shares up in pre-market trading following a solid 2020 outlook.
Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split
by Kinjel Shah
Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.
AbbVie (ABBV) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 0.45% and 0.03%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.
Regeneron Expands Agreement to Develop Coronavirus Therapy
by Zacks Equity Research
Regeneron (REGN) expands its agreement with U.S. Department of Health and Human Services for development of a therapy for newly found coronavirus.
Can Humira/Cancer Drugs Help AbbVie (ABBV) Beat Q4 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs are likely to have witnessed strong growth.
AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs might demonstrate strong growth.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $82.30, marking a +1.58% move from the previous day.
Vaxart (VXRT) to Make Vaccines to Check Coronavirus, Stock Up
by Zacks Equity Research
Vaxart (VXRT) begins a program to develop a vaccine candidate to counter the new coronavirus infection. Shares jump.
Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study
by Zacks Equity Research
Lilly's (LLY) JAK inhibitor Olumiant meets primary endpoint of phase III BREEZE-AD5 study, evaluating the drug as a monotherapy in atopic dermatitis patients.
Amgen (AMGN) Stock Down Despite Q4 Earnings & Revenue Beat
by Zacks Equity Research
Amgen (AMGN) stock declines despite better-than-expected fourth-quarter 2019 results. Its 2020 earnings guidance falls short of expectations.